BLS Shares BLS Pharmaceuticals Limited
ASX · ASXLast in our picks 2026-10-17 — not in the current list; analysis below is from that screen
Rapid share-price momentum and profitable pharmaceutical growth offer upside, albeit with heightened volatility.
Future value: $1.35 (+21.62%) · 6-12 months
Signal breakdown
- ▸185.5% annual momentum and moderate earnings valuation
- ▸Above 50-day MA (+6.29%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (80.4% of range) — strength
- ▸~22% upside to price target
Is BLS a buy right now?
Trend: BLS is trading below the 50-day average (-4.76%), RSI 65 — neutral momentum, with a 3-month return of +25.00%.
Valuation & quality: BLS Pharmaceuticals Limited trades on a trailing P/E of 14.3, PEG 2.67, price-to-book 7.41; fundamentals show net margin 20.8%, return on equity 71.3%, revenue growth 154.5% year on year.
Our screen: STRONG BUY (score 5) — Rapid share-price momentum and profitable pharmaceutical growth offer upside, albeit with heightened volatility.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +6.70% | -9.40% | +37.90% | +16.30% | -12.90% | +30.90% | -0.90% | -4.80% |
Fundamentals
Technical signals
About BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.